hcaii

Histone acetyltransferase p300 Inhibitor 4c is a 2-aminothiazole derivative. Histone acetyltransferase p300 Inhibitor 4c inhibited hCA I, hCA II, AChE and BChE with Ki values of 0.008 ± 0.001, 0.124 ± 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 µM. 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM.

hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. It is not blood-brain barrier permeable.

hCAII-IN-3 (Compound 16) is an inhibitor of human carbonic anhydrase (hCA) with high affinity for hCA I, hCA II, hCA IX, and hCA XII, exhibiting Ki values of 403.8 nM, 5.1 nM, 10.2 nM, and 5.2 nM, respectively. Notably, hCA IX-IN-2 demonstrates anticancer activity [1].

hCAII-IN-2 is a cytoplasmic human carbonic anhydrase (hCA) inhibitor that acts on hCA I (Ki: 261.4 nM), hCA II (Ki: 3.8 nM), hCA IX (Ki: 19.6 nM) and hCA XII (Ki: 45.2 nM).

hCAII IX-IN-1 (compound 4o) is a potent inhibitor of hCAII and hCAIX, with Ki values of 7.4 nM and 7.0 nM, respectively. It plays a significant role in cancer research.

Compound R-13, also known as hCAII-IN-7, is a powerful inhibitor of human carbonic anhydrase (hCA), exhibiting inhibition constants (Ki) of 60.7 nM for hCA I, 320.7 nM for hCA II, 2298 nM for hCA IV, and 35.2 nM for hCA IX, respectively [1].

hCAII-IN-5 (compound 12h) is a potent and selective inhibitor of human carbonic anhydrase II (hCA II) with an inhibition constant (IC50) of 4.55 µM [1].

hCAII-IN-4 (Compound 12j) is a potent inhibitor of human carbonic anhydrase II (hCA II) with an IC50 of 7.78 μM, and also inhibits β-glucuronidase with an IC50 of 773.9 μM [1].

β-Glucuronidase hCAII-IN-2 is a potent inhibitor of β-glucuronidase and hCA II, and their IC50 values were 670.7 μM and 21.77 μM, respectively.

hCAII-IN-6 (Compound S-13), a potent inhibitor of human carbonic anhydrase II (hCA II) with a K i of 4.4 nM, also exhibits inhibitory activity against other hCA isoforms, namely I, IV, and IX, with K i values of 9.2 nM, 480.2 nM, and 14.7 nM, respectively. It is utilized in glaucoma research [1].

hCAII XII-IN-1 (compound 4l) is a potent inhibitor of hCAXII and hCAII, with Ki values of 8.4 nM and 9.4 nM, respectively. It plays a significant role in cancer research.

hCAIX-IN-5 was a selective hCAIX inhibitor, inhibiting hCAI, hCAII, hCAIV, and hCAIX with Ki values of >10000, >10000, 130.7, and 829.1 nM, respectively.

hCAII-IN-1 (compound 7f) is a selective, potent inhibitor of carbonic anhydrase (CA II IX) with Ki values of 1.2 nM and 113.6 nM, respectively, demonstrating investigational potential for cancer.

β-Glucuronidase hCAII-IN-2 (Compound 12e) effectively inhibits β-glucuronidase and human Carbonic Anhydrase II (hCA II) with IC50 values of 440.1 μM and 4.91 μM, respectively [1].

Methazolamide (CL 8490) is a carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

compound EMAC10101d, bearing a 2,4-dichorophenyl substituent in position 4 of the dihydrothiazole ring, was the most potent and selective toward hCA II with an inhibitory activity in the low nanomolar range.

hCAIX XII-IN-3 (compound 6q) is a potent, selective inhibitor of hCAIX and hCAXII, with K i values of >10000 nM for hCAI and hCAII, and 66.2 nM and 4.4 nM for hCAIX and hCAXII, respectively.

hCAIX XII-IN-14 (Compound 1i) is an inhibitor of hCAIX and hCAXII, with Ki values of 9.4 nM for hCAII, 5.6 nM for hCAIX, and 6.3 nM for hCAXII.

hCAXII-IN-5 (compound 6o) is a highly effective and specific inhibitor of hCAXII, demonstrating impressive binding affinities with Ki values of >10000, >10000, 286.1, and 1.0 nM for hCAI, hCAII, hCAIX, and hCAXII, respectively [1].

hCAII-IN-3 (compound 7e) is a selective and potent inhibitor of carbonic anhydrase (CA II IX), with Ki values of 124.2 nM and 30.5 nM, respectively. hCAII-IN-1 shows investigational potential for cancer disease.

hCAI II XII-IN-1 (compound 7) is an inhibitor of human carbonic anhydrases hCAI, hCAII, and hCAXII, with Ki values of 78.5 nM, 9.1 nM, 605 nM, 7.7 nM, and 3.7 nM.

hCAIX-IN-18 (compound 30), a potent inhibitor of the carbonic anhydrase enzyme family (CA), exhibits K i values of 3.5 nM for hCAI, 9.4 nM for hCAII, 43.0 nM for hCAIX, and 8.2 nM for hCAXII. This compound is applicable in cancer research [1].

hCAIX-IN-7 (compound 6c) is a potent and selective inhibitor of the tumor-associated isoform hCAIX, with inhibition constants (KIs) of >10000 nM for hCAI and hCAII, 43.0 nM for hCAIV, and 410.6 nM for hCAIX [1].

hCAIX XII-IN-2 (compound 6a) is a potent and selective inhibitor of hCAIX and hCAXII, with Ki values of >10000 nM for hCAI and hCAII, and 30.0 nM and 3.6 nM for hCAIX and hCAXII respectively [1].